YBX1 and neoplasm: siRNA and ASO specifically degrade YBX1 mRNA to reduce protein expression, while PROTACs induce ubiquitin-mediated degradation of YBX1, enabling rapid and efficient protein clearance, thereby reversing tumor drug resistance and immune suppression (26).